Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Oct
14
Today In Oncology
Creatine
Incidence of Invasive Lobular Carcinoma Rising Faster Than Other Breast Cancers
Gaps Persist in Follow-Up Care Among Young Survivors of Breast Cancer
Ziftomenib in Relapsed or Refractory NPM1-Mutant AML
Advanced Biliary Tract Cancer Adding a Polymeric Micellar Paclitaxel to Gemcitabine Plus Cisplatin
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo